Pervasis Therapeutics to Present Data from Phase 1 and 2 Clinical Trials of Vascugel(R) at the American Society of Nephrology 41st Annual Meeting and Scientific Exposition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, today announced that data from the company’s Phase 1 and Phase 2 trials of Vascugel® V-HEALTH (Vascular intimal Hyperplasia: Extending Arterial and venous patency, Limiting vascular Trauma, and inhibiting Hyperplasia while re-establishing vascular health) will be presented at the American Society of Nephrology 41st Annual Meeting and Scientific Exposition during Renal Week 2008 in Philadelphia, Pennsylvania.